Collegium Pharmaceutical, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
VRXValeant Pharmaceuticals International, Inc. -1.38%22.2114.1%$130.69m
AMRNAmarin Corp. Plc -2.12%14.361.7%$97.40m
CTLTCatalent, Inc. -1.56%51.632.2%$72.34m
JAZZJazz Pharmaceuticals Plc 0.76%113.962.3%$62.96m
UTHRUnited Therapeutics Corp. 0.97%101.7614.3%$60.06m
GWPHGW Pharmaceuticals Plc -1.69%102.706.2%$56.20m
AXSMAxsome Therapeutics, Inc. -2.27%79.811.9%$48.96m
PRGOPerrigo Co. Plc -1.31%51.146.8%$48.68m
HZNPHorizon Therapeutics Plc 0.69%34.306.6%$45.77m
RVMDRevolution Medicines, Inc. -3.02%31.190.0%$44.13m
ZGNXZogenix, Inc. 1.73%24.109.4%$40.97m
MNKMallinckrodt Plc 4.74%4.2020.9%$37.83m
ENDPEndo International Plc -3.11%5.468.8%$37.81m
ICPTIntercept Pharmaceuticals, Inc. 0.66%85.9516.9%$36.05m
ICLRICON plc 0.21%157.014.2%$32.57m

Company Profile

Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in October 2003 and is headquartered in Stoughton, MA.